We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,673.00
Bid: 1,674.00
Ask: 1,675.00
Change: 3.00 (0.18%)
Spread: 1.00 (0.06%)
Open: 1,661.50
High: 1,679.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-We're unlikely to see a repeat of late 2018 rout

Wed, 30th Oct 2019 11:44

* European shares flat before Fed meeting
* Fiat Chrysler and PSA confirm tie-up talks, stocks rally
* Bank earnings in focus: DB, CS, StanChart, Santander
* Fed seen cutting rates, focus on policy outlook

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your
thoughts on market moves: rm://julien.ponthus.thomsonreuters.com@reuters.net

WE'RE UNLIKELY TO SEE A REPEAT OF LATE 2018 ROUT (1144 GMT)
So far we haven't seen any signs of a repeat of last year's fourth-quarter rout that
instilled fear that the bull market was coming to an end.
"They (investors) seem to be worried about a repeat of the painful de-risking seen in
November and December last year, but we believe it is unlikely to materialise," Barclays equity
strategists led by Emmanuel Cau say in a note.
The deeply unloved rally continues and Cau says hedge funds have reduced their equity shorts
but are not net long yet while exposure to bonds is still crowded.
"Investors' dislike of equities lowers the odds of another episode of painful year-end
derisking and suggests the bar for positive surprises is not high."
On rotation, Barclays says value rotation could get fresh legs to run if activity momentum
stabilises and central banks do not surprise on the dovish side anymore.
Here's a chart on high 2020 earnings expectations and market's de-risking in late 2018, when
2019 expectations came of rails:


(Thyagaraju Adinarayan)
*****


UK HOUSEBUILDERS ON ELECTION WATCH (0945 GMT)
So now we have an election date -- Dec. 12 -- and housebuilders are among the sectors that
could be affected.
Liberum has taken a look and how the industry fared in the run up to the past voting rounds
and crossing that with current indications from polls showing a Tory majority win, concludes
there might be an opportunity here for investors.
"If history is a guide we should expect the housing market to slow in the run-up to the
announced general election, but if the opinion polls and bookmakers are correct, the
housebuilders shares could outperform if a Conservative victory is the outcome," analyst at
Liberum say.
"It is difficult to see a clear picture in how housebuilders' shares perform immediately
before or after a general election, although we do note that the sector performed well during
the 2015 and 2017 elections won by the Conservatives," they add.


(Danilo Masoni)
*****



OPENING SNAPSHOT: PSA AND FIAT CHRYSLER STEALS THE SHOW (0828 GMT)
It's the main headline of the day so it's only fair in a way that PSA and Fiat
Chrysler get the spotlight this morning with their shares surging 8.7% and 7.5%
respectively.
The French carmaker is the top performer on its home turf and same goes for its Italian
would-be match in Milan. The brides are well in the race for the top spot on the STOXX 600
.
Although both stocks are on fire, they will struggle to catch up Germany's Fuchs Petrolub
which jumped about 12% on the back of better-than-expected earnings.
It's not only fun and joy in the sector though with Renault, PSA's arch rival,
falling 4% as its shareholders are probably getting a big blast of Fomo.
What could also curb the enthusiasm for the sector is Pirelli's 5.5 percent fall
after the tyre maker cut its guidance.
It seems to a good day for France Inc with L'Oreal up 6 percent as it defies the
perceived gloom of the Chinese market. The French benchmark is up 0.2%.
Plenty of action in the banking sector with Deutsche Bank posting the worst
performance of the DAX with a 4% fall after yet another quarterly loss.
Bayer on the other hand took the lead for German blue chips, rising 2.5% on solid
results.
Because the overall market has no clear directional trend yet, here's a look at the top
movers on the STOXX 600 instead:

(Julien Ponthus)
*****


ON THE RADAR: CORPORATE TOP NEWS OVERLOAD (0736 GMT)
Futures have opened sideways with no clear directional trend in Europe.
What's clear however is that there is such a huge flow of corporate news that it will be
difficult to be sure not to have missed anything before the open and the market, which tends to
be quite unforgiving these days, gives its verdict.
Before getting in the Q3 action, let's first flag out a major piece of news in the auto
industry with Fiat Chrysler confirming talks with French rival PSA for a
potential tie-up.
News of the tentative merger comes as Germany's Volkswagen lowered its full-year
outlook for vehicle deliveries, warning of slowing demand.
Lots to take in the banking industry too:
Deutsche Bank reports 832 million euro Q3 loss on restructuring
StanChart flags growth, interest rate headwinds after Q3 profit beat
Credit Suisse doubles Q3 net profit

Santander Q3 net profit falls 75% as UK charges offset Brazil strength

But there are heavyweights across all sectors making headlines this morning so in no
particular order, he's the rest of the top news: click here to get it on Eikon:
Airbus cuts delivery goal on Hamburg plant snags
Record Q3 output boosts Total's cash flow, low prices hit profit
Lower oil and gas prices weigh on OMV Q3 profit
Bayer says number of glyphosate plaintiffs jumps to 42,700

Clariant Q3 profit and sales fall as economic climate worsens
Angry Birds maker Rovio's Q3 profit halves year-on-year
EssilorLuxottica confirms 2019 targets after stronger Q3 sales
Britain's Next keeps full year guidance after Q3 sales rise
(Julien Ponthus)
*****


FED WATCHING, Q3 GALORE AND THE XMAS BREXIT ELECTION (0542 GMT)
Christmas will come early to the UK this year, precisely on December 12 in the form of a UK
general election.
It's far from certain however that the polls will deliver anything on Boris Johnson or
Jeremy Corbyn's wish list but less than 48 hours ahead of Halloween, investors aren't spooked by
the prospect of the process going all wrong.
The pound is roughly stable at 1.2870 and according to IG, financial spreadbetters expect
London's FTSE to open just 7 points lower, so nothing dramatic there indeed.
Frankfurt's DAX is also seen retreating slightly at the open by 25 points but Paris is
should be flat.
With Wall Street on and off record highs, the Fed's meeting today and the expected interest
rate cut will be key, especially after it emerged that Washington and Beijing may not complete
their interim trade agreement in time to sign in Chile next month.
Amid all that news let us not forget that we are in for one of the busiest day of the Q3
season with a flurry of results such as Bayer, GlaxoSmithKline, Suez
or Total.
Last but not least, there will also be a deluge of indicators from the euro zone which
should shed more light on whether there is light to be seen at the end of the macro gloom
tunnel.
(Julien Ponthus)
*****


(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.